FDA Approved: REVCOVI — Original Application (Chiesi USA, Inc.)

View source ↗

Summary

FDA approved REVCOVI (elapegademase-lvlr) from Chiesi USA as a first-in-class enzyme replacement therapy for ADA-deficiency–associated severe combined immunodef…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenosine Deaminase Deficiency Associated Severe Combined Immunodeficiency

Drugs mentioned

• Revcovi (elapegadamase-lvlr)

Snippet

ORIG AP for REVCOVI (ELAPEGADEMASE-LVLR)